$CELG Recent News What to do while the institutions sit

New Post Public Reply Private Reply Replies (0) Message Board

Feb 15, 2015 at 12:04 PM

$CELG Recent News

What to do while the institutions sit on the sideline 3:26 p.m. Feb. 5, 2015 - The Trading Deck
Celgene revenue rises on cancer-drug sales 8:04 a.m. Jan. 29, 2015 - MarketWatch.com
Major U.S. benchmarks challenge last-ditch support 11:31 a.m. Jan. 20, 2015 - Michael Ashbaugh
Major U.S. benchmarks challenge last-ditch support 11:09 a.m. Jan. 20, 2015 - Michael Ashbaugh
Some of the Nasdaq’s leading lights have begun to dim 2:02 p.m. Jan. 15, 2015 - The Trading Deck
GameStop shares rally on strong holiday sales 5:48 p.m. Jan. 13, 2015 - MarketWatch
Celgene shares gain 3.6% to top S&P 500 9:40 a.m. Jan. 13, 2015 - Sue Chang
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Updates, advisories and surprises 12:31 p.m. Jan. 12, 2015 - MarketWatch
Celgene's 2015 profit outlook is below forecasts 12:18 p.m. Jan. 12, 2015 - MarketWatch.com
Celgene's stock rises, but off highs after profit outlook 11:48 a.m. Jan. 12, 2015 - Tomi Kilgore
Celgene's stock gains 1.2% after Q4 profit view tops expectations 11:26 a.m. Jan. 12, 2015 - Tomi Kilgore
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:27 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:55 p.m. Dec. 24, 2014 - Carla Mozee
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:10 p.m. Dec. 9, 2014 - The Trading Deck

Jim Cramer's Stop Trading: Apache Has Room to Rise, J&J Takes It on the Chin 1:19 p.m. Feb. 13, 2015 - TheStreet.com
'Mad Money' Lightning Round: Just Say No to Conoco Stock 6:00 a.m. Feb. 13, 2015 - TheStreet.com
Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15) 5:32 a.m. Feb. 13, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Buy the Best and Leave the Rest 8:12 p.m. Feb. 12, 2015 - TheStreet.com
3 Stocks Pushing The Drugs Industry Lower 12:03 p.m. Feb. 12, 2015 - TheStreet.com
Regional Banks Are The Way To Go - Cramer's Lightning Round (2/11/15) 6:05 a.m. Feb. 12, 2015 - Seeking Alpha
'Mad Money' Lightning Round: Buy, Buy, Buy Boeing Below $140 6:00 a.m. Feb. 12, 2015 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Get Ready to Profit on Europe-Induced Weakness 8:14 p.m. Feb. 11, 2015 - TheStreet.com
Celgene Up on Abraxane Getting Positive Recommendation - Analyst Blog 4:59 p.m. Feb. 11, 2015 - Zacks.com
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy 4:31 p.m. Feb. 11, 2015 - Seeking Alpha
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog 11:47 a.m. Feb. 11, 2015 - Zacks.com
Short Sellers Look Scared of Big Biotech 8:52 a.m. Feb. 11, 2015 - 247WallSt.com
'Mad Money' Lightning Round: Stop Fretting and Buy, Buy, Buy Sirius XM 6:00 a.m. Feb. 11, 2015 - TheStreet.com
Baxter Needs To Split Up - Cramer's Lightning Round (2/10/15) 5:28 a.m. Feb. 11, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News 8:35 p.m. Feb. 10, 2015 - TheStreet.com
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea 10:01 a.m. Feb. 10, 2015 - Investors Business Daily
Celgene: Good Q4 2014, Outlook Is Good To Great Going Forward 4:55 p.m. Feb. 9, 2015 - Seeking Alpha
No Deceleration Here: 14 Stocks With Accelerating Profits 5:29 p.m. Feb. 6, 2015 - Investors Business Daily
4 (More) Biotech Stocks to Buy 8:06 a.m. Feb. 6, 2015 - InvestorPlace.com
OncoMed Starts Dosing in Non-Small Cell Lung Cancer Study - Analyst Blog 4:20 p.m. Feb. 5, 2015 - Zacks.com

Celgene Announces Positive Recommendation by Scottish Medicines Consortium (SMC) for ABRAXANE® (Nab-Paclitaxel) in combination with Gemcitabine1 for Patients with Metastatic Pancreatic Cancer 2:02 a.m. Feb. 10, 2015 - BusinessWire - BZX
Critical Alerts For Juno Therapeutics Inc, Westport Innovations, Disney, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Feb. 5, 2015 - PR Newswire - PRF
Biotech Stocks Scanner - ARIAD Pharma, Celgene, CytRx, Amicus Therapeutics, and United Therapeutics 9:00 a.m. Feb. 4, 2015 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences 8:30 a.m. Jan. 27, 2015 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer 7:19 a.m. Jan. 23, 2015 - BusinessWire - BZX
Critical Alerts For Apple, VoxelJet, Celgene, TASER International and Finisar Released By InvestorsObserver 9:31 a.m. Jan. 22, 2015 - PR Newswire - PRF
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter 8:45 a.m. Jan. 21, 2015 - PR Newswire - PRF
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 12:24 p.m. Jan. 16, 2015 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 9:10 a.m. Jan. 16, 2015 - BusinessWire - BZX
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's 8:40 a.m. Jan. 14, 2015 - PR Newswire - PRF
Biotechs to Follow in 2015 off Fresh Insider Moves 10:00 a.m. Jan. 6, 2015 - ACCESSWIRE
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:31 a.m. Jan. 6, 2015 - BusinessWire - BZX
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Battery Testing Market to Reach $45 Billion by 2033

There's a gold rush happening in the battery testing market, as ambitious as any I've seen in my trading years. The market's taking off faster than a Wall Street trader on a bull market open, projected to skyrocket from $13.03 billion in 2026 to $45.06 billion by 2033. That's a hefty 19.4% compound annual growth rate, a pace that'll have big money and new players...

JELD-WEN Alters Exchange Consideration for 2027 Notes

Navigating the Turbulent Waters of Note Exchanges Well folks, it looks like JELD-WEN Holding, Inc. is making waves again. The company has decided to shake things up a bit with a new twist on the note exchange comedy script. They’re altering the terms of the late exchange consideration for their outstanding 4.875% Senior Notes due 2027, making the latecomers to the party...

Asset Based Lending's $200M Securitization: A Power Move

Well, folks, Asset Based Lending (ABL) in Jersey City just pulled a rabbit out of a challenging market hat, hammering out their heftiest securitization yet—a crisp $200 million deal. This isn't just pocket change, even for a seasoned player like ABL. Let's dive into what makes this move not just hefty in size, but a strategic punch in the current landscape of...

Porte Brown Hits #3 for Young Accountants in 2026

Fresh Faces Rank Porte Brown High Now here's a thing most big-name firms might envy—Porte Brown nabbed the #3 spot on Accounting Today's 2026 list of Best Firms for Young Accountants. This isn't some fly-by-night recognition; it speaks to their whole gig—nurturing, training, and growing young talent in the world of numbers. When you talk about setting the bar for...

Yael Eckstein Honored for Advancing Faith Collaborations

Recognition for Bridging Communities It's not every day you hear about someone getting a pat on the back as broad as a lifetime achievement award. Yet, Yael Eckstein, President and Global CEO of the International Fellowship of Christians and Jews (The Fellowship), managed just that during an elegant gala in Jerusalem. The Black Christian Leadership Council on Israel...

Frontera Energy: Solid Gains Amid Strategic Expansions

Thriving in a Complex Energy World You know, for Frontera Energy Corporation, it's not just about tossing around tanker loads of cash—it’s about working those numbers into something real. Their Q3 2026 gives us a peep into how they’re keeping the hot iron pressed against opportunity. With a net income of $11.7 million and adjusted EBITDA jumping 16% to top $34.8...

Oman Unveils Groundbreaking China Investment Package

Transforming Oman-China Relations Through Investment Let me tell you, this one's a hefty shake-up in the Middle East’s economic scene. Oman’s pulling in billions with its latest move, signing the biggest bundle of investment agreements in its history, all thanks to some heavy-handed diplomacy between the Sultanate’s top brass and Chinese financial muscle. We're...

Reagan Institute's New Fellowship: Academic Game-Changer

Aiming for an Academic Revival There’s hope on the horizon for academics wrestling to find their foothold among hallowed university halls. The Reagan Institute Society of Fellows is opening new doors for early career scholars. With heavyweight partners like Dartmouth and George Washington University joining forces, this is a solid lifeline amidst a sea of fading...

BrightView's Tumbling Shares Prompt Investor Inquiry

BrightView's Financial Quagmire: Investor Alarm Bells Ring Just when you thought it couldn't get any rockier for BrightView Holdings (NYSE: BV), here comes another gut punch. Their Development Services segment—once a promising player—felt like it dropped off a cliff, tumbling by almost 18%. If you were counting on those revenues to keep things afloat, well, it seems...

NKT's Power Cable Triumph: Elbe Crossing Success

NKT's Sweeping Success at the Elbe Crossing In one spellbinding leap, NKT just crossed the River Elbe with their specially engineered power cables like a high-wire act over a natural canyon. We're talking about the SuedLink project—a massive undertaking to link up Germany's power grid. Now, NKT didn't just drop a couple of cables under this river. They delivered 525 kV...